Related Experiment Video
Updated: Sep 17, 2025

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
PDE-5 inhibition mitigates mental stress-induced endothelial dysfunction in resistant hypertension
Amanda Sampaio Storch1,2, Helena Naly Miguens Rocha1,2, Joao Dario Mattos2
1Laboratory of Integrative Cardiometabology, Department of Physiology and Pharmacology, Fluminense Federal University, Niterói, Brazil.
None:
Resistant hypertension (RH) is associated with an increased risk of adverse cardiovascular events, and mental stress (MS) is one of the major risk factors. We aimed to test the hypothesis that a phosphodiesterase 5 inhibitor (iPDE5) would minimize the deleterious effects of MS on the endothelial function of those patients. In two experimental days, patients with RH (63 ± 5 yr; 30.2 ± 3.1 kg/m2) received iPDE5 (sildenafil citrate; 50 mg) or a placebo (PL) pill, in a randomized, crossover, double-blind, and placebo-controlled clinical trial. After 30 min, subjects underwent a 5-min MS task (modified Stroop Color-Word Test). Flow-mediated dilatation (FMD) and blood flow (BF) measurements (vascular ultrasound), pulse wave analysis (applanation tonometry), and blood sampling (for vasoactive substances and cGMP measurements) were performed at baseline, during or immediately after MS, and 30 min after MS (MS30). Blood pressure, heart rate, and BF increased during the MS task in both conditions (P ≤ 0.02 vs. rest). FMD decreased immediately after MS (P < 0.01 vs. baseline) and MS30 (P < 0.01 vs. baseline) in the PL condition, whereas it was higher in MS (P = 0.03 vs. PL) and MS30 (P < 0.01 vs. baseline; P = 0.04 vs. MS; P < 0.01 vs. PL) in the iPDE5 condition. Peripheral and central systolic blood pressures were lower while plasma nitrate and cGMP were higher in the iPDE5 condition throughout the protocol (P ≤ 0.04 vs. rest). Present data suggest that iPDE5 prevents MS-induced endothelial dysfunction and improves cardiovascular hemodynamics in RH.NEW & NOTEWORTHY Considering that mental stress (MS)-induced endothelial dysfunction causes major cardiovascular events, the present study explored the involvement of NO-cGMP pathway in resistant hypertension (RH) pathophysiology. Our results suggest that phosphodiesterase 5 inhibition prevents endothelial dysfunction and improves cardiovascular hemodynamics of patients with resistant hypertension faced with stressful circumstances.
More Related Videos
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Hypertension II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...